US Pharma MarketingBiohaven looks to take on Lilly in the muscle-sparing obesity space
Biohaven Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
They say that the way to make money in a gold rush is to open a shop selling picks and shovels. By the same token, perhaps companies can profit from the GLP-1 boom by developing ...
Source: Endpoints News